Purpose: The contribution of serial prostate specific antigen (PSA) determinations was studied to obtain better understanding of the natural history of clinically confined prostate carcinoma.
Our study was done to contribute to a better understanding of the natural history of clinically confined prostate carcinoma and to determine the contribution of serial prostate specific antigen (PSA) measurements. For this reason PSA determinations were correlated with the clinical course in 29 patients in whom a policy of watchful waiting was applied. In several studies increasing PSA levels predicted later clinical progression.'-4 The interval between both events depends on tumor stage at diagnosis or treatment. Regarding the correlation of PSA increase and progression in stages T1 and T2 tumors with time, little information is available in the literature. With regard to the uncertainties of identifying local progression it may well be possible that an increase in PSA level is a more accurate indicator of progressive disease in these patients.
PATIENTS AND METHODS
We evaluated retrospectively 29 patients with histologically confirmed adenocarcinoma of the prostate from the time of diagnosis until the time of first treatment, if any, for cancer-related progression. Mean patient age was 74 years (range 58 to 85), and mean followup was 39 months (range 11 to 73). Stage was assessed clinically by digital rectal examination according to the 1992 TNM classification.6 In 15 patients with stage Tla disease previously unsuspected carcinoma was found in the transurethral resection specimens. Grade was determined according to the Anderson classification.6 Metastatic disease was excluded by a normal chest x-ray and a normal bone scan. The decision not to treat at diagnosis was made by the urologist in discussion with the patient and his family, with respect to patient age, general health, clinical stage and patient preference. All patients were considered to have a probable survival of at least 1 year.
Followup. Local and metastatic progression was evaluated. Subjective progression, like obstructive micturition or pain, was considered for treatment decisions. Local subjective progression occurred in most patients at the same time as or later than local objective progression. Local objective progression was defined as an increase in T category, when prostate size increased on digital rectal examination by 25% or more of the products of the 2 largest perpendicular parameters, or by an ultrasound measured volume of more than 40%. Objective metastatic progression was diagnosed by the appearance of new lesions on a bone scan. Bone scans were performed for initial staging and afterwards when indicated only. For the purpose of defining clinical progression, an increase in serum evaluate differences among various groups of patients regarding these slopes. The level of statistical significance was set at p = 0.05 (2-tailed). The relationship between progression rates and PSA level or its change from the baseline value was evaluated using Cox regression allowing for time-dependent variables.' The relationship between PSA levels and simultaneous prostate volume measurements, allowing for inter-patient and intra-patient differences, was assessed by computer using regression analysis.
RESULTS
During followup 13 of 29 patients had local progression after a mean of 31 months. Metastatic progression was not noted. Of these patients with progression 6 started therapy: 5 for subjective symptoms at or within 3 months after progression and 1 for objective progression only. Two patients with local objective and subjective progression did not begin therapy. Disease did not progress in 16 patients (mean followup 40 months). Figure 1 shows the Kaplan-Meier curves for interval to progression for all patients, and for stage T l versus stages T2
to T3 and grade 1 versus grades 2 to 3 cancer. There was no statistical difference in interval to progression among the different grades or the Werent T categories. The mean number of PSA recordings per patient was 8.7. Figure 2 shows the scatterplots of PSA with time in linear plotting for patients with and without clinical progression. Slopes of PSA regression curves comparing progressive and nonprogressive disease were not signiscantly Merent. Figure 3 shows a plot of the PSA doubling time for the individual patients, separated
for those with and without progression. Also, a percentage PSA increase from a baseline of 20% with time was tested as an indicator of progression ( fig. 4) . At no point on the individual curves was it possible to predict clinical progression. The same applied to the cutoff level of a 50% increase in PSA with time.
Longitudinal measurements of ultrasonic prostatic volume were made in 14 patients. The mean annual increase in )rostatic volume in these patients was 15%. The mean in-:rease in volume was not significantly different between jatients with and without progression. A volume increase of nore than 40%, which would qualify a patient for clinical xogression on the basis of transrectal ultrasonography, was lot observed. There was a weak, although significant, correlation between volume and PSA ( fig. 5) . Changes in both parameters within patients, however, were not significantly related to each other.
DISCUSSION
In our study an attempt was made to identify the rate and interval of progression in 29 patients with locally confined prostate cancer treated by a policy of watchful waiting. In no instance was systemic progression observed during an average observation of 31 months. Local progression was identifiable as an increase in T category or as a palpable increase in prostate size in conjunction with subjective progression of the tumor.8 A volume increase on transrectal ultrasound of 40% or more was not ~bserved.~ PSA increase was independently studied and compared with clinical progression.
Our information presented is likely to be biased by patient selection and is certainly not representative of men for whom radical prostatectomy would normally be recommended. However, the data may be compatible with patient populations presented in other surveillance studies, such as those summarized in the overview by Chodak et a1.l0 The selection bias is reflected in the high average patient age, large proportion of grade 1 Several methods of analyzing PSA increase have been applied. PSA velocity, which represents the absolute annual PSA increase, was used by Carter et a1 in a select group of 52 men to discriminate between prostate carcinoma and benign disease." A discriminatory cutoff value of 0.75 ng./ml. per year was not confirmed by Brawer et a1 in a communitybased population of 701 men.l6 In that study the participants underwent further evaluation by digital rectal examination when the PSA level increased more than 20% within 1 year. Prostate carcinoma was found eventually in 5% of these men. Oesterling et a1 noted an age independent annual increase in PSA among several age groups in a community-based cohort of 376 men.l6 The mean annual increase in PSA was 5.1 to 11.4% but it was extremely variable partly due to the fact that the followup was 1 year and only 2 PSA measurements were obtained. In 1.1% of the cases carcinoma developed, with a mean annual PSA increase of 59%.
In our study increases in PSA with time could not discnmhate between nonprogressive, often incidentally found, lo- calized prostate carcinoma and progressive disease. Also, the annual PSA increases during year 1,2 or 3 of the evaluation were not markers for progression, which means that although there was a wide variety in PSA velocity and PSA doubling times ( fig. 3) , these parameters were not useful in these cases for this study period.
Our report confirms the PSA doubling time for organconfined prostate carcinoma found in other studies. al the PSA doubling time in 11 patients with confined disease versus 5 with progression to metastasis was not statistically different. 18 Carter et al mentioned that the linear increase in PSA level between patients with benign prostatic hyperplasia and prostatic carcinoma (up to diagnosis) was statistically different but from the PSA curves it is obvious that this PSA velocity has no prognostic value.14 A low PSA level has been associated with long-term survival in a study by Belville et al of 26 patients with stage A1 prostate carcinoma.l9 The patients had an age distribution similar to that of our study population (median age 72 years).
All tumors had well differentiated histology. Of the PSA levels 96% were less than 3.0 ngJml. Evaluation aRer a median followup of 12.5 years showed that in all patients the prostate carcinoma remained localized, although 6 (23%) had Droeression to a DdDable staee. Of our 14 values less than 10 ng./ml. 5 had progression. Only physician dependent initiation of therapy was found to be more frequent in patients with higher PSA values. Transrectal ultrasonic volumetry was not helpful as a parameter for progression.
CONCLUSIONS
In our study population, and probably in similarly select groups of patients, watchful waiting is considered justified. The absence of metastatic progression is at variance with other findings in the literature.20.21 On the basis of our study however, it appears to be safe to follow patients with PSA determinations, rectal examination, and the intermittent evaluation of related symptoms and signs. It must be realized that clinical progression may occur without changes in serum PSA.
